XML 78 R68.htm IDEA: XBRL DOCUMENT v3.22.2.2

Segment Reporting - Sales from Products (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Segment Reporting Information [Line Items]
Sales	$ 14,959	$ 13,154	$ 45,453	$ 35,183
Revenue related to the sale of the marketing rights			156	191
U.S.
Segment Reporting Information [Line Items]
Sales	7,322	6,276	20,927	16,166
Int’l
Segment Reporting Information [Line Items]
Sales	7,637	6,878	24,526	19,017
Operating Segments
Segment Reporting Information [Line Items]
Sales	14,334	12,913	44,146	35,021
Operating Segments | U.S.
Segment Reporting Information [Line Items]
Sales	7,095	6,137	20,544	15,974
Operating Segments | Int’l
Segment Reporting Information [Line Items]
Sales	7,239	6,777	23,601	19,047
Corporate, Non-Segment
Segment Reporting Information [Line Items]
Sales	625	241	1,307	162
Corporate, Non-Segment | U.S.
Segment Reporting Information [Line Items]
Sales	227	139	383	192
Corporate, Non-Segment | Int’l
Segment Reporting Information [Line Items]
Sales	398	101	925	(30)
Pharmaceutical | Operating Segments
Segment Reporting Information [Line Items]
Sales	12,963	11,496	39,826	30,714
Pharmaceutical | Operating Segments | U.S.
Segment Reporting Information [Line Items]
Sales	6,620	5,670	19,119	14,611
Pharmaceutical | Operating Segments | Int’l
Segment Reporting Information [Line Items]
Sales	6,343	5,826	20,707	16,103
Pharmaceutical | Operating Segments | Keytruda
Segment Reporting Information [Line Items]
Sales	5,426	4,534	15,487	12,609
Pharmaceutical | Operating Segments | Keytruda | U.S.
Segment Reporting Information [Line Items]
Sales	3,331	2,580	9,307	7,108
Pharmaceutical | Operating Segments | Keytruda | Int’l
Segment Reporting Information [Line Items]
Sales	2,095	1,954	6,180	5,501
Pharmaceutical | Operating Segments | Alliance revenue - Lynparza
Segment Reporting Information [Line Items]
Sales	284	246	825	721
Pharmaceutical | Operating Segments | Alliance revenue - Lynparza | U.S.
Segment Reporting Information [Line Items]
Sales	144	129	427	371
Pharmaceutical | Operating Segments | Alliance revenue - Lynparza | Int’l
Segment Reporting Information [Line Items]
Sales	140	117	397	350
Pharmaceutical | Operating Segments | Alliance revenue - Lenvima
Segment Reporting Information [Line Items]
Sales	202	188	660	498
Pharmaceutical | Operating Segments | Alliance revenue - Lenvima | U.S.
Segment Reporting Information [Line Items]
Sales	142	114	426	287
Pharmaceutical | Operating Segments | Alliance revenue - Lenvima | Int’l
Segment Reporting Information [Line Items]
Sales	60	74	235	211
Pharmaceutical | Operating Segments | Alliance Revenue - Reblozyl
Segment Reporting Information [Line Items]
Sales	39	0	124	0
Pharmaceutical | Operating Segments | Alliance Revenue - Reblozyl | U.S.
Segment Reporting Information [Line Items]
Sales	32	0	87	0
Pharmaceutical | Operating Segments | Alliance Revenue - Reblozyl | Int’l
Segment Reporting Information [Line Items]
Sales	7	0	37	0
Pharmaceutical | Operating Segments | Gardasil/Gardasil 9
Segment Reporting Information [Line Items]
Sales	2,294	1,993	5,428	4,144
Pharmaceutical | Operating Segments | Gardasil/Gardasil 9 | U.S.
Segment Reporting Information [Line Items]
Sales	957	839	1,803	1,605
Pharmaceutical | Operating Segments | Gardasil/Gardasil 9 | Int’l
Segment Reporting Information [Line Items]
Sales	1,337	1,154	3,624	2,539
Pharmaceutical | Operating Segments | ProQuad/M-M-R II/Varivax
Segment Reporting Information [Line Items]
Sales	668	661	1,716	1,626
Pharmaceutical | Operating Segments | ProQuad/M-M-R II/Varivax | U.S.
Segment Reporting Information [Line Items]
Sales	532	537	1,337	1,255
Pharmaceutical | Operating Segments | ProQuad/M-M-R II/Varivax | Int’l
Segment Reporting Information [Line Items]
Sales	136	125	379	371
Pharmaceutical | Operating Segments | RotaTeq
Segment Reporting Information [Line Items]
Sales	256	227	644	593
Pharmaceutical | Operating Segments | RotaTeq | U.S.
Segment Reporting Information [Line Items]
Sales	154	135	427	364
Pharmaceutical | Operating Segments | RotaTeq | Int’l
Segment Reporting Information [Line Items]
Sales	102	92	218	229
Pharmaceutical | Operating Segments | Pneumovax 23
Segment Reporting Information [Line Items]
Sales	131	277	457	600
Pharmaceutical | Operating Segments | Pneumovax 23 | U.S.
Segment Reporting Information [Line Items]
Sales	68	181	280	354
Pharmaceutical | Operating Segments | Pneumovax 23 | Int’l
Segment Reporting Information [Line Items]
Sales	63	97	177	247
Pharmaceutical | Operating Segments | Vaqta
Segment Reporting Information [Line Items]
Sales	64	48	134	138
Pharmaceutical | Operating Segments | Vaqta | U.S.
Segment Reporting Information [Line Items]
Sales	27	32	72	80
Pharmaceutical | Operating Segments | Vaqta | Int’l
Segment Reporting Information [Line Items]
Sales	36	16	62	58
Pharmaceutical | Operating Segments | Bridion
Segment Reporting Information [Line Items]
Sales	423	369	1,244	1,096
Pharmaceutical | Operating Segments | Bridion | U.S.
Segment Reporting Information [Line Items]
Sales	233	181	665	545
Pharmaceutical | Operating Segments | Bridion | Int’l
Segment Reporting Information [Line Items]
Sales	190	188	579	551
Pharmaceutical | Operating Segments | Prevymis
Segment Reporting Information [Line Items]
Sales	114	96	310	270
Pharmaceutical | Operating Segments | Prevymis | U.S.
Segment Reporting Information [Line Items]
Sales	49	39	136	111
Pharmaceutical | Operating Segments | Prevymis | Int’l
Segment Reporting Information [Line Items]
Sales	64	57	174	159
Pharmaceutical | Operating Segments | Dificid
Segment Reporting Information [Line Items]
Sales	77	54	196	115
Pharmaceutical | Operating Segments | Dificid | U.S.
Segment Reporting Information [Line Items]
Sales	72	52	184	108
Pharmaceutical | Operating Segments | Dificid | Int’l
Segment Reporting Information [Line Items]
Sales	6	2	12	7
Pharmaceutical | Operating Segments | Primaxin
Segment Reporting Information [Line Items]
Sales	63	70	185	194
Pharmaceutical | Operating Segments | Primaxin | U.S.
Segment Reporting Information [Line Items]
Sales	0	0	1	0
Pharmaceutical | Operating Segments | Primaxin | Int’l
Segment Reporting Information [Line Items]
Sales	63	69	185	194
Pharmaceutical | Operating Segments | Noxafil
Segment Reporting Information [Line Items]
Sales	62	64	180	197
Pharmaceutical | Operating Segments | Noxafil | U.S.
Segment Reporting Information [Line Items]
Sales	13	19	39	48
Pharmaceutical | Operating Segments | Noxafil | Int’l
Segment Reporting Information [Line Items]
Sales	49	45	141	149
Pharmaceutical | Operating Segments | Invanz
Segment Reporting Information [Line Items]
Sales	50	53	148	157
Pharmaceutical | Operating Segments | Invanz | U.S.
Segment Reporting Information [Line Items]
Sales	2	(2)	4	(2)
Pharmaceutical | Operating Segments | Invanz | Int’l
Segment Reporting Information [Line Items]
Sales	48	55	144	159
Pharmaceutical | Operating Segments | Cancidas
Segment Reporting Information [Line Items]
Sales	43	56	138	168
Pharmaceutical | Operating Segments | Cancidas | U.S.
Segment Reporting Information [Line Items]
Sales	1	1	5	4
Pharmaceutical | Operating Segments | Cancidas | Int’l
Segment Reporting Information [Line Items]
Sales	42	56	133	164
Pharmaceutical | Operating Segments | Zerbaxa
Segment Reporting Information [Line Items]
Sales	43	(2)	120	(11)
Pharmaceutical | Operating Segments | Zerbaxa | U.S.
Segment Reporting Information [Line Items]
Sales	24	(1)	64	(5)
Pharmaceutical | Operating Segments | Zerbaxa | Int’l
Segment Reporting Information [Line Items]
Sales	19	(1)	55	(6)
Pharmaceutical | Operating Segments | Alliance revenue - Adempas/Verquvo
Segment Reporting Information [Line Items]
Sales	88	100	258	248
Pharmaceutical | Operating Segments | Alliance revenue - Adempas/Verquvo | U.S.
Segment Reporting Information [Line Items]
Sales	85	73	244	222
Pharmaceutical | Operating Segments | Alliance revenue - Adempas/Verquvo | Int’l
Segment Reporting Information [Line Items]
Sales	3	27	14	26
Pharmaceutical | Operating Segments | Adempas
Segment Reporting Information [Line Items]
Sales	57	59	181	188
Pharmaceutical | Operating Segments | Adempas | U.S.
Segment Reporting Information [Line Items]
Sales	0	0	0	0
Pharmaceutical | Operating Segments | Adempas | Int’l
Segment Reporting Information [Line Items]
Sales	57	59	181	188
Pharmaceutical | Operating Segments | Lagevrio
Segment Reporting Information [Line Items]
Sales	436	0	4,859	0
Pharmaceutical | Operating Segments | Lagevrio | U.S.
Segment Reporting Information [Line Items]
Sales	0	0	1,523	0
Pharmaceutical | Operating Segments | Lagevrio | Int’l
Segment Reporting Information [Line Items]
Sales	436	0	3,336	0
Pharmaceutical | Operating Segments | Isentress/Isentress HD
Segment Reporting Information [Line Items]
Sales	161	189	466	590
Pharmaceutical | Operating Segments | Isentress/Isentress HD | U.S.
Segment Reporting Information [Line Items]
Sales	68	77	196	222
Pharmaceutical | Operating Segments | Isentress/Isentress HD | Int’l
Segment Reporting Information [Line Items]
Sales	93	112	270	368
Pharmaceutical | Operating Segments | Belsomra
Segment Reporting Information [Line Items]
Sales	62	81	199	238
Pharmaceutical | Operating Segments | Belsomra | U.S.
Segment Reporting Information [Line Items]
Sales	20	23	60	56
Pharmaceutical | Operating Segments | Belsomra | Int’l
Segment Reporting Information [Line Items]
Sales	42	58	139	183
Pharmaceutical | Operating Segments | Simponi
Segment Reporting Information [Line Items]
Sales	173	203	540	619
Pharmaceutical | Operating Segments | Simponi | U.S.
Segment Reporting Information [Line Items]
Sales	0	0	0	0
Pharmaceutical | Operating Segments | Simponi | Int’l
Segment Reporting Information [Line Items]
Sales	173	203	540	619
Pharmaceutical | Operating Segments | Remicade
Segment Reporting Information [Line Items]
Sales	49	73	163	233
Pharmaceutical | Operating Segments | Remicade | U.S.
Segment Reporting Information [Line Items]
Sales	0	0	0	0
Pharmaceutical | Operating Segments | Remicade | Int’l
Segment Reporting Information [Line Items]
Sales	49	73	163	233
Pharmaceutical | Operating Segments | Januvia
Segment Reporting Information [Line Items]
Sales	717	852	2,252	2,445
Pharmaceutical | Operating Segments | Januvia | U.S.
Segment Reporting Information [Line Items]
Sales	332	365	958	997
Pharmaceutical | Operating Segments | Januvia | Int’l
Segment Reporting Information [Line Items]
Sales	385	487	1,294	1,448
Pharmaceutical | Operating Segments | Janumet
Segment Reporting Information [Line Items]
Sales	417	487	1,347	1,449
Pharmaceutical | Operating Segments | Janumet | U.S.
Segment Reporting Information [Line Items]
Sales	90	86	258	244
Pharmaceutical | Operating Segments | Janumet | Int’l
Segment Reporting Information [Line Items]
Sales	327	401	1,089	1,205
Pharmaceutical | Operating Segments | Other pharmaceutical
Segment Reporting Information [Line Items]
Sales	564	518	1,565	1,589
Pharmaceutical | Operating Segments | Other pharmaceutical | U.S.
Segment Reporting Information [Line Items]
Sales	244	210	616	637
Pharmaceutical | Operating Segments | Other pharmaceutical | Int’l
Segment Reporting Information [Line Items]
Sales	321	306	949	950
Animal Health | Operating Segments
Segment Reporting Information [Line Items]
Sales	1,371	1,417	4,320	4,307
Animal Health | Operating Segments | U.S.
Segment Reporting Information [Line Items]
Sales	475	467	1,425	1,363
Animal Health | Operating Segments | Int’l
Segment Reporting Information [Line Items]
Sales	896	951	2,894	2,944
Animal Health | Operating Segments | Livestock
Segment Reporting Information [Line Items]
Sales	829	864	2,486	2,503
Animal Health | Operating Segments | Livestock | U.S.
Segment Reporting Information [Line Items]
Sales	186	190	521	508
Animal Health | Operating Segments | Livestock | Int’l
Segment Reporting Information [Line Items]
Sales	643	675	1,965	1,996
Animal Health | Operating Segments | Companion Animals
Segment Reporting Information [Line Items]
Sales	542	553	1,834	1,804
Animal Health | Operating Segments | Companion Animals | U.S.
Segment Reporting Information [Line Items]
Sales	289	277	904	855
Animal Health | Operating Segments | Companion Animals | Int’l
Segment Reporting Information [Line Items]
Sales	$ 253	$ 276	$ 929	$ 948

X

- Definition

The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 12
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585

+ Details

Name:	us-gaap_ProceedsFromSaleOfIntangibleAssets
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

+ Details

Name:	us-gaap_Revenues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingInformationLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	srt_StatementGeographicalAxis=country_US
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_StatementGeographicalAxis=mrk_InternationalMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=mrk_KeytrudaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=mrk_AlliancerevenueLynparzaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=mrk_LenvimaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=mrk_AllianceRevenueReblozylMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=mrk_GardasilGardasil9Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=mrk_ProQuadMMRIIVarivaxMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=mrk_RotateqMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=mrk_Pneumovax23Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=mrk_VaqtaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=mrk_BridionMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=mrk_PrevymisMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=mrk_DificidMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=mrk_PrimaxinMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=mrk_NoxafilMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=mrk_InvanzMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=mrk_CancidasMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=mrk_ZerbaxaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=mrk_AllianceRevenueAdempasVerquvoMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=mrk_AdempasMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=mrk_LagevrioMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=mrk_IsentressIsentressHDMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=mrk_BelsomraMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=mrk_SimponiMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=mrk_RemicadeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=mrk_JanuviaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=mrk_JanumetMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=mrk_OtherPharmaceuticalMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=mrk_LivestockMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=mrk_CompanionAnimalsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: